

NYX
NO PATIENT UNSEEN

THE PROBLEM

Silent Deterioration

1


400,000+
preventable deaths

2

80%
Show Preventable Warning Signs

3

50%
lack continuous monitoring



THE PROBLEM
Current Solutions



EXPENSIVE



BULKY



INTERMITTENT

MEET NYX



SOLUTION

THE HEADBAND

- Soft fabric with breathable mesh panels
- Lightweight design (<50g)
- Tested for 48+ hour continuous wear (Rechargeable Battery)




SOLUTION

The NYX Process



NOTIFY

Place headband, streaming begins immediately



YIELD

Real time vital sign trends, Multi sensor conformation



X-ECUTE

Nurse responds, system logs automatically

SOLUTION

TESTING & SAFETY

Software Validation:



Final Metric	Heart Rate	Respiratory	Temperature	Motion
AUC	0.9512	0.9438	0.9356	0.9402
Accuracy	0.8927	0.9173	0.8845	0.9215
Precision	0.8734	0.8956	0.8621	0.8987
Specificity	0.9156	0.9287	0.8934	0.9324
Sensitivity	0.8698	0.8842	0.8512	0.8976

Regulations Needed:

- ✓ FDA510(k)
- ✓ IEC 60601-1
- ✓ ISO 13485
- ✓ ISO 10993
- ✓ FCC
- ✓ HIPPA
- ✓ CYBERSECURITY

SOLUTION

Technical Details



Hardware Design

System Architecture

SOLUTION

THE SOFTWARE

Daily Report — Ward 3B

February 15, 2026

GENERATED

24

PATIENTS

576

MONITOR
HOURS

12

ALERTS

3

ESCALATIONS

Download PDF

Send to EMR

ENCRYPTED DATA PIPELINE



NyX
Headband



Encrypted
BLE



Cloud
Processing



EMR System



AES-256

HIPAA

HL7 FHIR

COMPATIBLE SYSTEMS

Epic

Cerner

MEDITECH

Allscripts

CLINICIAN DAILY SUMMARY

Feb 15, 2026

PATIENT	HR	SPO ₂	TEMP	EVENTS	
M. Santos 3B-01	72	98%	98.6°	None	—
J. Mitchell 3B-02	88	95%	99.8°	HR spike at 14:20	↗
S. Chen 3B-04	68	99%	97.9°	None	—
R. Davis 3B-05	105	92%	101.2°	SpO ₂ drop, escalated	↗
E. Rodriguez 3B-07	75	97%	98.2°	None	↘
W. Park 3B-08	90	94%	100.1°	Temp trending up	↗

SOLUTION

UNIQUE VALUE PROPOSITION

V

Value-Driven Accessibility

I

Integration by Design

T

Trusted Reliability


A

Affordable at Scale

L

Long-Term Sustainability

THE CONSUMERS MARKET ANALYSIS




ICU Monitor	Consumer Wearable	NYX
\$3,500–\$8,000+	\$200–\$400	<\$100 + Subscription

THE BUSINESS

THE BUSINESS MODEL

Revenue Streams	Product Kits	Software Subscription	Bulk Product Kits
What is it?	Heaband + Batteries + Manual	AI enabled Summary + One tap Calibration	Product Kits for orders > 150
Pricing	\$85-100	\$115 - 300	\$85 - 90
Profit Margin	31%	60%	28%

DISTRIBUTION OF REVENUE



THE BUSINESS

LONG TERM FINANCIAL PROJECTION

Income Statement (2026-2029)	Year 1 (Jun 2026 – May 2027)	Year 2 (Jun 2027 – May 2028)	Year 3 (Jun 2028 – May 2029)	Year 4 (Jun 2029 – May 2030)	Year 5 (Jun 2030 – May 2031)
REVENUE STREAMS					
Product Kits	193,000	275,000	520,000	750,000	1,000,000
Bulk Product Kits	144,000	210,000	x	625,000	900,000
Software Subscriptions	82,800	135,000	560,000	875,000	1,200,000
TOTAL REVENUE	419,800	620,000	1,550,000	2,250,000	3,100,000
EXPENSES					
Distribution Costs	31,496	45,000	93,000	135,000	175,000
Startup Costs	25,000	15,000	10,000	5,000	0
Operating Costs	35,000	50,000	75,000	95,000	120,000
Customer Acquisition Costs	23,000	35,000	70,000	90,000	110,000
Human Resource Costs	167,000	195,000	220,000	250,000	280,000
Production Costs	225,960	380,000	697,500	1,025,000	1,292,000
Research & Development	45,000	55,000	65,000	55,000	45,000
Regulatory & Compliance	15,000	25,000	35,000	25,000	20,000
Marketing & Sales	3,000	5,500	8,000	18,000	32,000
Operations & Admin	8,000	10,000	12,000	18,000	24,000
Depreciation	2,000	2,500	3,000	5,000	8,000
TOTAL EXPENSES	580,456	818,000	1,288,500	1,721,000	2,106,000
NET PROFIT	-160,656	-198,000	261,500	529,000	994,000

THE BUSINESS

TIMELINE & MARKET EXPANSION

PHASE 1
CLINICAL VALIDATION
(Q4 2025 - Q3 2026)

PHASE 2
INSTITUTIONAL ADOPTION
(Q4 2026–Q1 2027)

PHASE 3
SCALED DISTRIBUTION
(Q2–Q4 2027)

PHASE 4
PLATFORM EXPANSION
(2028 AND BEYOND)

THE BUSINESS
THE NYX TEAM



Shaunak Buche
Product Design Lead



Vedant Mehta
Software Lead



Kate Sharer
Clinical Validation Advisor



Dr. Suyog Buche
Regulatory & Compliance Advisor



Vishwa Rajan
Business Development Lead



Vedant Kalipatnapu
Biomedical Design Lead



Cathy O'Haver
Nursing Advisor



Dr. Avirup Guha
Engineering Advisor

PARTNERS:

